MRVI vs. DYN, GERN, ARDX, ARVN, RCKT, KROS, RYTM, DCPH, RNA, and PTCT
Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Dyne Therapeutics (DYN), Geron (GERN), Ardelyx (ARDX), Arvinas (ARVN), Rocket Pharmaceuticals (RCKT), Keros Therapeutics (KROS), Rhythm Pharmaceuticals (RYTM), Deciphera Pharmaceuticals (DCPH), Avidity Biosciences (RNA), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical preparations" industry.
Maravai LifeSciences (NASDAQ:MRVI) and Dyne Therapeutics (NASDAQ:DYN) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, community ranking, dividends, profitability and institutional ownership.
50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 0.2% of Maravai LifeSciences shares are held by company insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Maravai LifeSciences currently has a consensus price target of $11.44, suggesting a potential upside of 1.10%. Dyne Therapeutics has a consensus price target of $37.75, suggesting a potential upside of 36.38%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Maravai LifeSciences.
Maravai LifeSciences received 43 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Dyne Therapeutics an outperform vote while only 67.44% of users gave Maravai LifeSciences an outperform vote.
Maravai LifeSciences has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
Dyne Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -47.81%. Maravai LifeSciences' return on equity of -4.28% beat Dyne Therapeutics' return on equity.
In the previous week, Dyne Therapeutics had 6 more articles in the media than Maravai LifeSciences. MarketBeat recorded 12 mentions for Dyne Therapeutics and 6 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.91 beat Dyne Therapeutics' score of 0.14 indicating that Maravai LifeSciences is being referred to more favorably in the media.
Maravai LifeSciences has higher revenue and earnings than Dyne Therapeutics. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Dyne Therapeutics beats Maravai LifeSciences on 10 of the 17 factors compared between the two stocks.
Get Maravai LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maravai LifeSciences Competitors List
Related Companies and Tools
